公开(公告)号：US20200308132A1

公开(公告)日：2020-10-01

申请号：US16650746

申请日：2018-09-21

申请人： KINKI UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA ,  FUSO PHARMACEUTICAL INDUSTRIES, LTD.

发明人： Atsufumi KAWABATA ,  Fumiko SEKIGUCHI ,  Maho TSUBOTA ,  Naoki TOYOOKA ,  Hiroyuki NISHIKAWA

IPC分类号： C07D311/32 ,  A61P23/00

摘要： A new analgesic has been developed for T-type calcium channels as therapeutic targets.The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1): wherein each of R1 and R2 independently represents —H or —OH; R3 represents —OH; R4 represents —OH or —H; R5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms, or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.

公开(公告)号：US10533204B2

公开(公告)日：2020-01-14

申请号：US15314862

申请日：2015-05-29

申请人： NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA ,  SC WORLD, INC.

发明人： Hiroshi Hamana ,  Hiroyuki Kishi ,  Atsushi Muraguchi ,  Kiyomi Shitaoka

IPC分类号： C12P19/34 ,  C07K14/725 ,  C12Q1/6886 ,  A61K48/00

摘要： As a method for highly efficiently amplifying a TCR cDNA in a short period of time, there is provided a method for amplifying a T cell receptor (TCR) cDNA, which comprises the following step (1) and step (2): (1) the step of performing PCR by using at least one kind of the L primer mentioned below, the C primer 1 or UTR primer 1 mentioned below, and cDNA obtained from a single cell as the template to obtain an amplification product 1; an L primer of 30- to 60-nucleotide length comprising an adapter part of 15- to 25-nucleotide length, and a leader region-annealing part of 15- to 25-nucleotide length, which is ligated downstream from the adapter part, and can anneal to a part of a leader region containing a translation initiation codon, or an upstream part thereof, a C primer 1 of 15- to 25-nucleotide length, which can anneal to a part of a constant region, or a UTR primer 1 of 15- to 25-nucleotide length, which can anneal to a part of a 3′ untranslated region; (2) the step of performing PCR by using the adaptor primer mentioned below, the C primer 2 or UTR primer 2 mentioned below, and the amplification product 1 as the template to obtain an amplification product 2; an adapter primer of 15- to 25-nucleotide length, which can anneal to the adapter part of the amplification product 1, a C primer 2 of 15- to 25-nucleotide length, which can anneal to a part of the constant region existing upstream from the region to which the C primer 1 anneals, or a UTR primer 2 of 15- to 25-nucleotide length, which can anneal to a part of the 3′ untranslated region existing upstream from the region to which the UTR primer 1 anneals.

公开(公告)号：US20190322784A1

公开(公告)日：2019-10-24

申请号：US16348694

申请日：2017-11-09

申请人： THE UNIVERSITY OF TOYAMA ,  OSAKA ORGANIC CHEMICAL INDUSTRY CO., LTD.

发明人： Hiromi KITANO ,  Tadashi NAKAJI ,  Yoshiyuki SARUWATARI ,  Kazuyoshi MATSUOKA

IPC分类号： C08F220/26 ,  C08F220/58 ,  C08J3/28

摘要： Disclosed are a cell culture substrate that can be modified from its cell-inadhesibleness to make it cell-adhesible, by a convenient and low-cost treatment, and particularly, a substrate that allows position-specific culture of one or more kinds of cells. The substrate has on its surface a layer made of a photomodifiable polymer that comprises a monomer, as component (A), represented by Formula (1): wherein R1 denotes hydrogen or a methyl group, and R2 denotes an alkyl group having 1-22 carbon atoms, respectively, and n denotes an integer of 1-30, and a component (B) having a trialkoxysilyl group, which forms a layer.

公开(公告)号：US20180371583A1

公开(公告)日：2018-12-27

申请号：US15779971

申请日：2017-07-13

申请人： SUMITOMO ELECTRIC INDUSTRIES, LTD. ,  NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA

发明人： Manabu MIZUTANI ,  Katsuhito YOSHIDA ,  Nozomu KAWABE ,  Seiji SAIKAWA

IPC分类号： C22C23/02

CPC分类号： C22C23/02 ,  C22C23/00

摘要： A magnesium alloy is provided that includes: 5.0 mass % or more and 15.0 mass % or less of Al; 2.5 mass % or more and 7.0 mass % or less of Sr; 0.05 mass % or more and less than 3.0 mass % of Ca; and 0.1 mass % or more and 0.6 mass % or less of Mn, with a remainder including Mg and inevitable impurities.

公开(公告)号：US10023943B2

公开(公告)日：2018-07-17

申请号：US15092934

申请日：2016-04-07

申请人： National University Corporation University of Toyama ,  Ahresty Corporation

发明人： Seiji Saikawa ,  Gen Okazawa ,  Hiroshige Niwa ,  Kiyoshi Terayama ,  Susumu Ikeno ,  Emi Yanagihara ,  Shin Orii ,  Suguru Takeda

IPC分类号： C22C21/08 ,  C22C21/02 ,  C22C21/04 ,  B22D21/00

摘要： An Al—Mg—Si-based aluminum alloy includes 0.015 to 0.12 mass % of Sr, the aluminum alloy producing a cast metal structure in which Mg2Si is crystallized in a fine agglomerate form.

公开(公告)号：US09072718B2

公开(公告)日：2015-07-07

申请号：US13849302

申请日：2013-03-22

申请人： Kracie Pharma, Ltd. ,  National Cancer Center ,  National University Corporation University of Toyama

发明人： Toshiki Okubo ,  Satoshi Yomoda ,  Takafumi Fuse ,  Takanori Kawashima ,  Hiroyasu Esumi ,  Chika Miyoshi ,  Shigetoshi Kadota

IPC分类号： A01N65/00 ,  A61K36/28 ,  A61K31/365 ,  A61K31/7048 ,  C07D307/33

CPC分类号： A61K36/28 ,  A61K31/365 ,  A61K31/7048 ,  A61K2236/19 ,  C07D307/33

摘要： PROBLEM TO BE SOLVEDThe present invention is intended to provide a burdock fruit extract comprising arctigenin and arctiin at a definite ratio and a method for producing the same. More particularly, the present invention is intended to provide a method for producing a burdock fruit extract comprising arctigenin and arctiin at a weight ratio of approximately 1:1.SOLUTIONA method for producing a burdock fruit extract comprising arctigenin and arctiin at a weight ratio of arctigenin/arctiin=0.7 to 1.3 is provided, including the steps of: cutting a burdock fruit and converting arctiin which is inherent in the burdock fruit into arctigenin by enzymatic conversion by beta-glucosidase which is inherent in the burdock fruit, wherein the enzymatic conversion includes reaction at a temperature from 20° C. to 50° C. Also provided is the method further including a step of extracting an extract comprising arctigenin and arctiin by adding an organic solvent and heating to reflux.

摘要翻译： 待解决的问题本发明旨在提供一种以确定的比例含有弓形虫属和弓形虫的牛蒡果实提取物及其制造方法。 更具体地，本发明旨在提供一种生产牛蒡果实提取物的方法，所述牛蒡果实提取物包含重量比为约1:1的抗坏血酸和铁蛋白。 解决方案提供一种生产牛蒡果实提取物的方法，该方法包括以赤霉素/ arctinin = 0.7〜1.3的重量比计含有赤霉素和arctiin的方法，包括以下步骤：将牛蒡水果切割成牛蒡果实固有的arctiin， 牛蒡果实中固有的β-葡糖苷酶进行酶转化，其中酶促转化包括在20℃至50℃的温度下进行反应。还提供了一种方法，其还包括提取包含抗坏血酸和脯氨酸的提取物的步骤 通过加入有机溶剂并加热回流。

公开(公告)号：US20140377360A1

公开(公告)日：2014-12-25

申请号：US14358588

申请日：2012-11-09

申请人： National University Corporation University of Toyama

发明人： Tadashi Nakaji ,  Hiromi Kitano ,  Chirag Harsharan Singh Gujral

IPC分类号： A61K38/18 ,  A61K38/17 ,  A61K9/16

CPC分类号： A61K38/185 ,  A61K9/1641 ,  A61K9/1647 ,  A61K9/167 ,  A61K9/5031 ,  A61K9/5036 ,  A61K38/1709 ,  A61K38/18 ,  A61K38/1825 ,  A61K38/1858 ,  A61K38/1866 ,  A61K38/2066 ,  A61K38/30

摘要： A composition for controlled release of a physiologically active substance can release a physiologically active substance in vivo at the desired timing. The composition includes an inner layer that is formed of a biodegradable substance that supports a physiologically active substance, and an outer layer that is formed of a biodegradable substance that differs from that of the inner layer.

摘要翻译： 用于控制释放生理活性物质的组合物可以在期望的时间在体内释放生理活性物质。 该组合物包括由支持生理活性物质的生物降解性物质形成的内层和由与内层不同的生物降解性物质形成的外层。

公开(公告)号：US11970549B2

公开(公告)日：2024-04-30

申请号：US17996601

申请日：2021-12-10

申请人： TOYOBO CO., LTD. ,  NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA

发明人： Takafumi Yoshikane ,  Nobuyuki Kurosawa ,  Masaharu Isobe

IPC分类号： C07K16/40

CPC分类号： C07K16/40 ,  C07K2317/565

摘要： The invention provides an antibody that specifically binds to a 5′ to 3′ exonuclease domain of a DNA polymerase, or a fragment thereof. The antibody inhibits the 5′ to 3′ exonuclease activity of a DNA polymerase, or a fragment thereof.

公开(公告)号：US20230295286A1

公开(公告)日：2023-09-21

申请号：US18020449

申请日：2021-11-24

申请人： National University Corporation University of Toyama

发明人： Seiji Yamamoto ,  Masakiyo Sasahara ,  Takeru Hamashima ,  Noriko Okuno

IPC分类号： C07K16/22 ,  C12N15/115 ,  C12N15/113 ,  A61P35/00

CPC分类号： C07K16/22 ,  C12N15/115 ,  C12N15/1136 ,  A61P35/00 ,  C12N2310/16 ,  C12N2310/14 ,  C12N2310/11

摘要： A pharmaceutical composition for preventing or treating cystic lymphangioma comprising an agent that causes suppression of expression of amphiregulin, suppression of secretion of amphiregulin, and/or inhibition of binding of amphiregulin with an amphiregulin receptor, or an agent that causes suppression of expression of an amphiregulin receptor, suppression of activation of an amphiregulin receptor, and/or inhibition of binding of an amphiregulin receptor with amphiregulin, as an active ingredient.

公开(公告)号：US20230293767A1

公开(公告)日：2023-09-21

申请号：US18021113

申请日：2020-10-30

申请人： National University Corporation University of Toyama ,  SAKURA SEIKI CO., LTD.

发明人： Michiro FUJISAKA ,  Hideo SHOJAKU ,  Shinsuke ITO ,  Toshiko YOSHIDA ,  Motonori OKABE ,  Chika SOKO ,  Masahiko ARAKAWA

IPC分类号： A61L27/36 ,  A61L27/54 ,  A61L27/60

CPC分类号： A61L27/3604 ,  A61L27/3691 ,  A61L27/54 ,  A61L27/60 ,  A61L2430/14

摘要： The present invention addresses the problem of providing a material as a scaffold used to prevent poor skin grafting when there is a defect in the perichondrium or periosteum or a defect in subcutaneous tissue. As a solution, there is provided a dry amniotic membrane manufactured according to a specific drying process. In more detail, a raw amniotic membrane placed in a processing tank (10) is continuously heated by a far-infrared heater (14) provided inside the processing tank (10), while performing a decompression operation where the interior of the processing tank (10) is placed in a decompressed state and irradiation of the raw amniotic membrane with microwaves from a microwave generating device (30) provided inside the processing tank (10) to apply energy to water molecules present inside the amniotic membrane and cause drying during a pressure recovery operation that slightly raises the pressure inside the depressurized processing tank (10) toward atmospheric pressure. By providing amniotic membrane, which has been dried by repeating the above process a plurality of times to retain its cellular and tissue structure, as a scaffold used to prevent poor skin grafting when there is a defect in the perichondrium or periosteum or a defect in the subcutaneous tissue, it is possible to enhance the healing effect of a skin graft.